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Abstract
Background The Risk Evaluation and Mitigation Strategy
(REMS) for retigabine/ezogabine (RTG/EZG) required an
evaluation of the effectiveness of the communication plan
to communicate about the risks with use of RTG/EZG.
Objective GlaxoSmithKline conducted a survey to assess
understanding of the risk of urinary retention (UR) with
RTG/EZG and to evaluate the effectiveness of the com-
munication plan.
Methods This was a US-based, cross-sectional, non-in-
terventional, observational survey, conducted from Febru-
ary to April 2013, of physicians who had prescribed RTG/
EZG in the past year, and pharmacists who had dispensed
an antiepileptic drug within the past 3 months. Thirteen
primary objective questions (five specific to UR risk) were
included in the survey, which assessed healthcare profes-
sionals’ (HCPs’) understanding of UR risk and symptoms
of acute UR associated with RTG/EZG. The primary out-
come was the proportion of HCPs correctly answering each
question. For each question, a proportion of correct
responses C80 % was considered to represent sufficient
understanding of associated risks.
Results Of 1028 HCPs screened, 373 participated. Six
of 13 questions (3/5 specific to UR risk) met the C80 %
Key Points
Survey results demonstrated a mixed level of
understanding of aspects of UR risk associated with
retigabine/ezogabine (RTG/EZG) among
prescribers.
Pharmacists displayed a lower level of understanding
than prescribers, probably due to the short time that
RTG/EZG had been available for prescription.
A key insight from the survey was that the questions
should be focused on the objective to assess specific
risks and evaluate effectiveness of the
communication plan, and additional questions should
not be included to avoid adding complexity.
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threshold for correct responses in the physician cohort.
No questions achieved this threshold in the total phar-
macist group; however, four questions scored C80 %
when stratified by pharmacists who had dispensed RTG/
EZG.
Conclusions Results demonstrated a mixed level of
understanding of aspects of UR risk associated with RTG/
EZG, although some risk questions did not meet the 80 %
threshold, especially among pharmacists. This is likely to
have been due to the short time that RTG/EZG has been
available and its limited use. This study provides the first
evaluation of the REMS communication plan on the risk of
UR with RTG/EZG.
1 Introduction
Retigabine (RTG; international nonproprietary name)/
ezogabine (EZG; US adopted name) is an antiepileptic
drug (AED) approved in the US (as POTIGATM,
GlaxoSmithKline [GSK] and Valeant) for the adjunctive
treatment of partial-onset seizures in adults who have
responded inadequately to several treatments and for
whom the benefits outweigh the risk of retinal abnor-
malities and potential decline in visual acuity [1]. In
clinical studies investigating the efficacy and safety of
RTG/EZG, an increased risk of urinary retention (UR)
was reported in patients receiving RTG/EZG compared
with placebo [2–6].
RTG/EZG was approved in June 2011 with a US Food
and Drug Administration (FDA) requirement for a Risk
Evaluation and Mitigation Strategy (REMS) [7]. According
to the FDA Amendments Act of 2007, the FDA may require
a drug manufacturer to submit a REMS, which is intended
to manage known or potential serious risks associated with a
drug and to ensure that the benefits of the drug outweigh the
risks [8, 9]. The REMS for RTG/EZG consisted of a com-
munication plan for healthcare professionals (HCPs),
including prescribing physicians and dispensing pharma-
cists, designed to disseminate information on the risk of UR
with RTG/EZG and highlight the importance of advising
patients to seek immediate attention for symptoms of UR,
including inability to urinate and/or pain with urination. The
communication plan had two elements: (i) a Dear Health-
care Professional (DHCP) letter, disseminated within
4 weeks of first retail availability (May 7, 2012) and
annually for the following 2 years; and (ii) a REMS pro-
gram website available at the time of launch (April 16,
2012; no longer active). The delay between the approval of
the new drug application (NDA; June, 2011) and retail
availability was caused by the requirement for RTG/EZG to
be reviewed by the US Drug Enforcement Administration
(DEA), in line with the Controlled Substances Act, in order
to determine the scheduling status.
As a condition of approval, the FDA required that GSK
assess this communication plan’s effectiveness. Accord-
ingly, a survey was conducted among a sample of HCPs to
evaluate knowledge of UR risk with RTG/EZG [10]. The
survey focused on the risks described in the DHCP letter
for RTG/EZG, and assessed where HCPs prefer to seek
information for RTG/EZG (e.g., DHCP letters, website,
product labeling). Here we report the results of this survey.
2 Methods
2.1 Study Design
This was a cross-sectional, non-interventional, observa-
tional survey of HCPs who prescribe RTG/EZG or dis-
pense AEDs. The study did not include intervention;
therefore, institutional review board approval was not
deemed necessary.
2.2 Sampling and Study Population
From a Concentrics Research market research partner’s
custom database of more than 668,000 geographically and
therapeutically diverse US HCPs, approximately 14,000
eligible physicians and pharmacists were contacted from a
demographically representative population who prescribe
RTG/EZG (neurologists, neurosurgeons, epileptologists),
or dispense AEDs (pharmacists). The original mailing list
for the DHCP letter included prescribers, emergency room
physicians and urologists, the HCPs most likely to come
into contact with RTG/EZG-treated patients who may have
UR symptoms. This survey focused only on recruiting
potential prescribers and the overlap between the DHCP
mailing list and the Concentrics database is not known.
2.3 Survey Inclusion, Exclusion, and Withdrawal
Criteria
Inclusion criteria included practicing physicians who had
prescribed RTG/EZG within the past year, and practicing
pharmacists who had filled a prescription for at least one
AED within the past 3 months. Physicians and pharmacists
currently employed by, or who were representatives of, a
pharmaceutical company or manufacturer of medicines or
healthcare products, or who were contributors to, or editors
of, published guideline committees for epilepsy or UR, were
ineligible. Additionally, HCPs who previously participated
in the pilot REMS study for RTG/EZG, or who were
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employees of GSK or Concentrics Research, were excluded.
HCPs could withdraw from the study at any time.
2.4 Screening and Baseline Assessments
HCPs were contacted initially by telephone, email, or fax
with an invitation to participate in the study, conducted
from February through April 2013. A standardized
screening questionnaire conducted by telephone assessed
eligibility, demographics, and interest in study participa-
tion. After recruitment, HCPs’ understanding of the
symptoms and risks of UR with RTG/EZG was evaluated
by means of an online survey or telephone interview.
Thirty closed-ended questions were asked to assess the
following: demographics and prescribing/dispensing his-
tory of each HCP; understanding of RTG/EZG key safety
messages based on US prescribing information and prac-
tices (13 primary objective questions [five specific to UR
risk]); and personal experience, awareness, receipt, and
dissemination of information about RTG/EZG (see elec-
tronic supplementary material).
2.5 Statistical Analysis
Baseline assessments were summarized by using propor-
tions (%) for categorical data. The primary outcome was
the proportion of HCPs correctly answering each question
related to understanding of risks associated with RTG/
EZG. At least 80 % of correct responses for each question
was considered to represent sufficient understanding of the
risks associated with RTG/EZG. This threshold was
determined on the basis of experience from similar studies
previously planned by GSK and approved by the FDA [11].
In a REMS workshop in July 2012, the FDA cites the 80 %
threshold as a level that is generally accepted for the survey
responses [12], though the discussion on setting standard-
ized thresholds for REMS assessments is ongoing [13]. The
proportion of correct answers to survey questions was
summarized overall and by demographic subgroups. Data
were grouped into subcategories to identify possible trends
in understanding, including demographics, type of HCP,




Of 1028 HCPs who were recruited and screened, 373
physicians (n = 168) and pharmacists (n = 205) completed
the survey (Fig. 1). All respondents completed the survey
online, and none completed the survey by phone.
3.2 Demographics and Baseline Characteristics
Physicians reported that their primary specialty was neu-
rology (64 %) or epileptology (36 %). Pharmacists repor-
ted community/retail (55 %) or hospital/clinic (45 %) as
their primary specialty. Most HCPs had been practicing
medicine/pharmacy and prescribing/dispensing AEDs for
5–35 years.
Prescribing physicians treated patients across all ages,
and most reported a total number of more than 1000
patients, more than 100 of whom had epilepsy. Sixty per-
cent of physicians had prescribed, and 41 % of pharmacists
had filled prescriptions for AEDs to more than 50 patients
monthly during the past year. Most pharmacists had not
dispensed (77 %) RTG/EZG or answered (83 %) patients’
questions about RTG/EZG in the past year. Of those who
had done so, 44 % reported having dispensed RTG/EZG
for only 1–3 months and most reported prescribing
(physicians, 52 %) or dispensing (pharmacists, 66 %)
RTG/EZG to only 1–2 patients within the past year.
3.3 Survey Results
The distribution of responses to questions assessing HCPs’
understanding of the risks associated with RTG/EZG is
shown in Table 1. Of the five questions related specifically
to the risk of UR associated with RTG/EZG, three (Q3, Q8,
Q13) were correctly answered by more than 80 % of
physicians and met the pre-defined threshold, whereas two
(Q7 and Q12) fell below the target threshold. Of the
questions not specifically related to UR risk, Q1, Q2, and
Q11.1 were answered correctly by more than 80 % of
physicians (Q11 was a single question with five parts that
are shown separately); the remaining questions (Q4, Q5,
Q6, Q9, Q10, Q11.2, Q11.3, Q11.4, Q11.5) had an average
percent correct response of 59 %.
None of the questions for the pharmacist cohort
achieved the 80 % threshold. However, when stratified by
pharmacists who had dispensed RTG/EZG (n = 32), the
established threshold was met by four questions (Q1, Q3,
Q8, Q11.1), two of which (Q3, Q8) were specifically
related to UR risk (Table 1).
A series of profiling questions asked HCPs how they
learned about the risks associated with RTG/EZG and
invited them to select up to three options for how they
would prefer to learn about such risks in the future.
Responses to these questions are presented in Table 2. The
majority of HCPs did not learn about the risks associated
with RTG/EZG from a DHCP letter. Notably, 82 % of
physicians and 91 % of pharmacists gave a negative
response when asked if the DHCP letter was their source of
information about RTG/EZG-associated risks. Most
physicians reported learning about these risks from the
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RTG/EZG product label (78 %) or from a GSK sales
representative (60 %), whereas pharmacists reported
learning from the RTG/EZG product label (46 %), other
HCPs (22 %), or the GSK product website (20 %).
Physicians reported interest in learning about the risks
associated with RTG/EZG in the future through GSK-
sponsored educational meetings (55 %), sales representa-
tives (46 %), or product labeling (36 %). Pharmacists
preferred to receive information from product labeling
(49 %), GSK-sponsored educational meetings (36 %),
sales representatives (35 %), or a DHCP letter (31 %).
4 Discussion
This study provides an indication of the effectiveness of the
RTG/EZG REMS communication plan, as evaluated by a
survey of prescribing physicians and dispensing pharma-
cists, to assess HCPs’ recall of the risks and symptoms of
UR associated with RTG/EZG. Overall, the surveyed
population encompassed HCPs with 5–35 years of expe-
rience in practice; most had considerable experience in
prescribing or dispensing AEDs. RTG/EZG has been
available only since May 2012, and prescribing of the drug
has been modest. Both of these factors explain the rela-
tively low level of experience in prescribing and dispensing
RTG/EZG among the HCPs surveyed.
The original proposal had been to survey all potential
AED prescribers, but the RTG/EZG launch was delayed
due to the DEA assessment of the scheduling status and
sales showed that RTG/EZG uptake was low, so the sample
of HCPs was enriched for those who had some experience
with RTG/EZG. The selection criteria differed between
prescribers and pharmacists. Prescribers were mainly spe-
cialists likely to see epilepsy patients, but pharmacists were
generalists and could not be assumed to have any experi-
ence with dispensing RTG/EZG. The shorter time period
for requiring dispensing of AEDs by pharmacists was
selected to enrich the possibility of pharmacist experience
with RTG/EZG.
Fig. 1 Flowchart of healthcare
provider screening. aThe most
common reason for termination
of physicians at time of
screening was not prescribing
RTG/EZG. bOne physician was
removed from the study due to
inconsistencies between
indicated primary specialty
during screening and on
questionnaire. RTG/EZG
retigabine/ezogabine
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Table 1 Summary of overall physician and pharmacist responses to risk questions, and pharmacist risk question responses by RTG/EZG
(POTIGATM) dispensing history















Q1 According to US prescribing information, what is the FDA-approved indication for POTIGATM?a
Migraine 2 (1.2) 1 (0.5) 1 (3.1) –
Partial-onset seizuresb 164 (97.6) 127 (62.0) 29 (90.6) 98 (56.6)
Generalized tonic clonic
seizures
9 (5.4) 6 (2.9) 3 (9.4) 3 (1.7)
None of the above – – – –
I don’t know 2 (1.2) 74 (36.1) 2 (6.3) 72 (41.6)
Q2 True or False: According to US prescribing information, POTIGATM can be used as monotherapy
True 8 (4.8) 29 (14.1) 9 (28.1) 20 (11.6)
Falseb 153 (91.1) 82 (40.0) 20 (62.5) 62 (35.8)
I don’t know 7 (4.2) 94 (45.9) 3 (9.4) 91 (52.6)
Q3 According to US prescribing information, which of the following are potential risks associated with POTIGATM?a
Urinary retentionb 143 (85.1) 117 (57.1) 26 (81.3) 91 (52.6)
Pancreatitis 9 (5.4) 5 (2.4) 3 (9.4) 2 (1.2)
Ischemic colitis 3 (1.8) 1 (0.5) 1 (3.1) –
I don’t know 19 (11.3) 85 (41.5) 4 (12.5) 81 (46.8)
Q4 According to US prescribing information, what is the maximum recommended daily maintenance dose
of POTIGATM for the general population?a
600 mg 11 (6.5) 10 (4.9) 4 (12.5) 6 (3.5)
900 mg 13 (7.7) 4 (2.0) 2 (6.3) 2 (1.2)
1200 mgb 114 (67.9) 105 (51.2) 24 (75.0) 81 (46.8)
2000 mg 1 (0.6) – – –
None of the above 4 (2.4) 6 (2.9) – 6 (3.5)
I don’t know 27 (16.1) 84 (41.0) 4 (12.5) 80 (46.2)
Q5 According to US prescribing information, which of the following statements, if any, is true?a
The oldest age at which
POTIGATM can be used is 65 y
6 (3.6) 2 (1.0) 1 (3.1) 1 (0.6)
There are no lower age limits for
POTIGATM
11 (6.5) 4 (2.0) 1 (3.1) 3 (1.7)
The youngest age at which
POTIGATM can be used is 12 y
22 (13.1) 11 (5.4) 5 (15.6) 6 (3.5)
The youngest age at which
POTIGATM can be used is 18 yb
104 (61.9) 85 (41.5) 18 (56.3) 67 (38.7)
None of the above 9 (5.4) 10 (4.9) 1 (3.1) 9 (5.2)
I don’t know 25 (14.9) 94 (45.9) 7 (21.9) 87 (50.3)
Q6 According to US prescribing information, which of the following statements, if any, is true?
POTIGATM should always be
taken with food
6 (3.6) 5 (2.4) 2 (6.3) 3 (1.7)
POTIGATM should always be
taken on its own, without food
2 (1.2) 3 (1.5) 3 (9.4) –
POTIGATM can be taken with or
without foodb
116 (69.0) 120 (58.5) 24 (75.0) 96 (55.5)
None of the above 2 (1.2) 1 (0.5) – 1 (0.6)
I don’t know 42 (25.0) 77 (37.6) 4 (12.5) 73 (42.2)
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Table 1 continued















Q7 Which of the following urinary symptoms, if any, should you specifically advise patients taking
POTIGATM to watch out for?a
Pain when urinatingb 38 (22.6) 47 (22.9) 14 (43.8) 33 (19.1)
Difficulty starting urinationb 98 (58.3) 97 (47.3) 24 (75.0) 73 (42.2)
Renal colic 17 (10.1) 10 (4.9) 3 (9.4) 7 (4.0)
Inability to urinateb 129 (76.8) 88 (42.9) 22 (68.8) 66 (38.2)
None of the above 1 (0.6) 1 (0.5) – 1 (0.6)
I don’t know 12 (7.1) 73 (35.6) 2 (6.3) 71 (41.0)
Q8 If a patient on POTIGATM experiences inability to pass urine, what would you advise them to do?a
Report the issue at their next
doctor’s appointment
6 (3.6) 25 (12.2) 6 (18.8) 19 (11.0)
Drink more water 6 (3.6) 6 (2.9) 2 (6.3) 4 (2.3)
Seek immediate medical
attentionb
139 (82.7) 138 (67.3) 26 (81.2) 112 (64.7)
Stop taking POTIGATM 68 (40.5) 26 (12.7) 6 (18.8) 20 (11.6)
None of the above 2 (1.2) 1 (0.5) – 1 (0.6)
I don’t know 3 (1.8) 44 (21.5) – 44 (25.4)
Q9 According to US prescribing information, when increasing the dose, what is the maximum total daily dose
at which POTIGATM can be increased once every 7 days?
Total daily dose increased by
50 mg/day
21 (12.5) 26 (12.7) 6 (18.8) 20 (11.6)
Total daily dose increased by
150 mg/dayb
100 (59.5) 88 (42.9) 19 (59.4) 69 (39.9)
Total daily dose increased by
200 mg/day
8 (4.8) – – –
Total daily dose increased by
300 mg/day
13 (7.7) 2 (1.0) 1 (3.1) 1 (0.6)
None of the above 4 (2.4) 1 (0.5) – 1 (0.6)
I don’t know 22 (13.1) 88 (42.9) 6 (18.8) 82 (47.4)
Q10 True or False: According to US prescribing information, for the general population, the recommended total
initial dosage should be 150 mg per day for one week
True 54 (32.1) 24 (11.7) 9 (28.1) 15 (8.7)
Falseb 92 (54.8) 102 (49.8) 22 (68.8) 80 (46.2)
I don’t know 22 (13.1) 79 (38.5) 1 (3.1) 78 (45.1)
Q11 The label for POTIGATM recommends caution when prescribing for patients with which of the following conditions, if any?
11.1 Moderate to severe renal or hepatic impairment
Yesb 147 (87.5) 133 (64.9) 28 (87.5) 105 (60.7)
No 8 (4.8) 9 (4.4) 2 (6.3) 7 (4.0)
I don’t know 13 (7.7) 63 (30.7) 2 (6.3) 61 (35.3)
11.2 Moderate to severe Crohn’s disease
Yes 18 (10.7) 20 (9.8) 6 (18.8) 14 (8.1)
Nob 87 (51.8) 62 (30.2) 18 (56.3) 44 (25.4)
I don’t know 63 (37.5) 123 (60.0) 8 (25.0) 115 (66.5)
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Generally, among physicians, the survey results
revealed a mixed level of understanding of several
aspects of the UR risk associated with RTG/EZG,
although a number of risk questions did not meet the
pre-defined 80 % correct response threshold. The lower
understanding of RTG/EZG-associated UR risk within
the pharmacist group can be explained by a lack of
familiarity and experience with dispensing RTG/EZG
among retail and hospital pharmacists due to the short
time that RTG/EZG has been available and its low rate
of prescribing.
Although the survey included a considerable number of
physicians and pharmacists, the sample may not be fully
representative of HCPs who prescribe or dispense RTG/
Table 1 continued















11.3 Moderate to severe asthma
Yes 6 (3.6) 12 (5.9) 3 (9.4) 9 (5.2)
Nob 106 (63.1) 72 (35.1) 21 (65.6) 51 (29.5)
I don’t know 56 (33.3) 121 (59.0) 8 (25.0) 113 (65.3)
11.4 Patients over the age of 65 years
Yes 93 (55.4) 90 (43.9) 24 (75.0) 66 (38.2)
Nob 39 (23.2) 22 (10.7) 6 (18.8) 16 (9.2)
I don’t know 36 (21.4) 93 (45.4) 2 (6.3) 91 (52.6)
11.5 Moderate to severe glaucoma
Yes 20 (11.9) 31 (15.1) 9 (28.1) 22 (12.7)
Nob 79 (47.0) 52 (25.4) 12 (37.5) 40 (23.1)
I don’t know 69 (41.1) 122 (59.5) 11 (34.4) 111 (64.2)
Q12 True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally
tend to be reported within the first 6 months after starting POTIGATM
Yes 124 (73.8) 94 (45.9) 25 (78.1) 69 (39.9)
Nob 8 (4.8) 8 (3.9) 2 (6.3) 6 (3.5)
I don’t know 36 (21.4) 103 (50.2) 5 (15.6) 98 (56.6)
Q13 Which of the following patient groups are recommended to have closer monitoring (including comprehensive
evaluation of urologic symptoms) for urinary retention?a
Patients with benign prostatic
hyperplasia (BPH)b
144 (85.7) 137 (66.8) 26 (81.3) 111 (64.2)




134 (79.8) 99 (48.3) 21 (65.6) 78 (45.1)
Patients who use concomitant
medications that may affect
voiding (e.g., anti-cholinergics)b
138 (82.1) 129 (62.9) 26 (81.3) 103 (59.5)
Patients who use non-steroidal
anti-inflammatory drugs
(NSAIDs)
13 (7.7) 33 (16.1) 5 (15.6) 28 (16.2)
Patients who are obese 4 (2.4) 12 (5.9) 3 (9.4) 9 (5.2)
None of the above 1 (0.6) 2 (1.0) – 2 (1.2)
I don’t know 11 (6.5) 57 (27.8) 2 (6.3) 55 (31.8)
The US branded name for RTG/EZG (POTIGATM) was used throughout the survey
FDA US Food and Drug Administration, RTG/EZG retigabine/ezogabine, – indicates a percentage that does not round to 1 or is zero
a Respondents could select more than one response
b Indicates correct responses
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Q29 Have you learned about the risks associated with the use of POTIGATM from any of the following sources?
29.1 POTIGATM Dear HCP letter
Yes 14 (8.3) 10 (4.9)
No 137 (81.5) 186 (90.7)
Don’t know 17 (10.1) 9 (4.4)
29.2 GlaxoSmithKline medical information
Yes 58 (34.5) 21 (10.2)
No 98 (58.3) 177 (86.3)
Don’t know 12 (7.1) 7 (3.4)
29.3 GlaxoSmithKline promotional materials
Yes 67 (39.9) 28 (13.7)
No 90 (53.6) 171 (83.4)
Don’t know 11 (6.5) 6 (2.9)
29.4 GSK website: POTIGA.com
Yes 39 (23.2) 41 (20.0)
No 118 (70.2) 159 (77.6)
Don’t know 11 (6.5) 5 (2.4)
29.5 GlaxoSmithKline sales representatives
Yes 100 (59.5) 9 (4.4)
No 64 (38.1) 190 (92.7)
Don’t know 4 (2.4) 6 (2.9)
29.6 GlaxoSmithKline-sponsored educational meeting
Yes 30 (17.9) 4 (2.0)
No 130 (77.4) 195 (95.1)
Don’t know 8 (4.8) 6 (2.9)
29.7 POTIGATM product labeling (including prescribing information, medication guide)
Yes 131 (78.0) 95 (46.3)
No 30 (17.9) 104 (50.7)
Don’t know 7 (4.2) 6 (2.9)
29.8 Other healthcare professionals
Yes 74 (44.0) 45 (22.0)
No 85 (50.6) 154 (75.1)
Don’t know 9 (5.4) 6 (2.9)
Q30 How would you prefer to learn about the risks associated with the use of POTIGATM in the future? (Select up to 3 options)
GlaxoSmithKline-sponsored educational meeting 92 (54.8) 74 (36.1)
GlaxoSmithKline sales representatives 77 (45.8) 71 (34.6)
POTIGATM product labeling (including
prescribing information, medication guide)
60 (35.7) 101 (49.3)
Other healthcare professionals 60 (35.7) 36 (17.6)
GlaxoSmithKline medical information 41 (24.4) 48 (23.4)
GSK website: POTIGA.com 37 (22.0) 61 (29.8)
GlaxoSmithKline promotional materials 28 (16.7) 60 (29.3)
POTIGATM Dear HCP letter 21 (12.5) 64 (31.2)
The US branded name for RTG/EZG (POTIGATM) was used throughout the survey. Among the 30 survey questions, questions Q29.1 through
Q30 pertained to HCP profiling
HCP healthcare provider, RTG/EZG retigabine/ezogabine
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EZG. To limit this potential bias, HCPs were recruited
from a large online database of geographically and
demographically diverse US HCPs, rather than by tar-
geting only high prescribers of RTG/EZG. Because the
small sample size in certain subgroups may have resulted
in low precision, data were grouped into appropriate
subcategories to identify possible trends in understanding.
As this was an online survey, it was not possible to detect
whether or not HCPs used any reference materials while
taking the survey.
Overall, in this first evaluation of the REMS commu-
nication plan to disseminate information on the risks of
UR associated with RTG/EZG treatment, physicians
demonstrated a mixed level of understanding of the
symptoms and of risks associated with RTG/EZG use.
Pharmacists displayed a lower level of understanding,
probably due to the short time that RTG/EZG has been
available for prescription. One key insight gained from
the survey was that the questions should be focused on the
specific risks, and the addition of extra questions to mask
the intent of the survey from respondents may have added
complexity and confusion. The EU survey was modified
accordingly following the REMS survey experience [14].
The results of the survey did not indicate a need for
alternative or additional measures, beyond the originally
proposed REMS measures, to enhance the understanding
of the risk of UR with POTIGATM. The FDA announce-
ment on pigmentation in retigabine patients was released
on 26 April 2013 [15]. At the start the survey, these risks
were not yet known. After the safety issues emerged, the
planned distribution of annual DHCP letters as part of the
original REMS was delayed in agreement with the FDA
and ongoing discussions took place with the FDA on the
next steps.
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